R. A. Bailey, Y. Wang, V. Zhu, and M. F. Rupnow, Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging, BMC Res Notes, vol.7, p.415, 2014.

A. I. Adler, R. J. Stevens, S. E. Manley, R. W. Bilous, C. A. Cull et al., Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64), Kidney Int, vol.63, issue.1, pp.225-257, 2003.

D. Verzola, L. Cappuccino, D. 'amato, E. Villaggio, B. Gianiorio et al., Enhanced glomerular Toll-like receptor 4 expression and signaling in patients with type 2 diabetic nephropathy and microalbuminuria, Kidney Int, vol.86, issue.6, pp.1229-1272, 2014.

I. M. Stratton, C. A. Cull, A. I. Adler, D. R. Matthews, H. A. Neil et al., Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75), Diabetologia, vol.49, issue.8, pp.1761-1770, 2006.

D. Fineberg, K. A. Jandeleit-dahm, and M. E. Cooper, Diabetic nephropathy: diagnosis and treatment, Nat Rev Endocrinol, vol.9, issue.12, pp.713-736, 2013.

J. Bellien, R. Joannides, V. Richard, and C. Thuillez, Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases?, Pharmacol Ther, vol.131, issue.1, pp.1-17, 2011.

J. Gao, J. Bellien, E. Gomez, J. P. Henry, B. Dautreaux et al., Soluble epoxide hydrolase inhibition prevents coronary endothelial dysfunction in mice with renovascular hypertension, J Hypertens, vol.29, issue.6, pp.1128-1163, 2011.

N. Merabet, J. Bellien, E. Glevarec, L. Nicol, D. Lucas et al., Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure, J Mol Cell Cardiol, vol.52, issue.3, pp.660-666, 2012.

P. Luo, H. H. Chang, Y. Zhou, S. Zhang, S. H. Hwang et al., Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis, J Pharmacol Exp Ther, vol.334, issue.2, pp.430-438, 2010.

A. Luria, A. Bettaieb, Y. Xi, G. J. Shieh, H. C. Liu et al., Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance, Proc Natl Acad Sci, vol.108, issue.22, pp.9038-9081, 2011.

X. Zhao, T. Yamamoto, J. W. Newman, I. H. Kim, T. Watanabe et al., Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage, J Am Soc Nephrol, vol.15, issue.5, pp.1244-53, 2004.

J. D. Imig, X. Zhao, C. Z. Zaharis, J. J. Olearczyk, D. M. Pollock et al., An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension, Hypertension, vol.46, issue.4, pp.975-81, 2005.

M. Manhiani, J. E. Quigley, S. F. Knight, S. Tasoobshirazi, T. Moore et al., Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension, Am J Physiol Renal Physiol, vol.297, issue.3, pp.740-748, 2009.

J. P. Lee, S. H. Yang, H. Y. Lee, B. Kim, J. Y. Cho et al., Soluble epoxide hydrolase activity determines the severity of ischemia-reperfusion injury in kidney, PLoS One, vol.7, issue.5, 2012.

. Roche, , vol.9

, Author manuscript; available in PMC, Prostaglandins Other Lipid Mediat, 2016.

Y. Liu, H. K. Webb, H. Fukushima, J. Micheli, S. Markova et al., Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor ?B signaling, J Pharmacol Exp Ther, vol.341, issue.3, pp.725-759, 2012.

O. Jung, F. Jansen, A. Mieth, E. Barbosa-sicard, R. U. Pliquett et al., Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease, PLoS One, vol.5, issue.8, 2010.

A. A. Elmarakby, J. Faulkner, M. Al-shabrawey, M. H. Wang, K. R. Maddipati et al., Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes, Am J Physiol Regul Integr Comp Physiol, vol.301, issue.5, pp.1307-1324, 2011.

J. Y. Liu, H. J. Tsai, S. H. Hwang, P. D. Jones, C. Morisseau et al., Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation, Br J Pharmacol, vol.156, issue.2, pp.284-96, 2009.

M. S. Remedi, S. E. Agapova, A. K. Vyas, P. W. Hruz, and C. G. Nichols, Acute sulfonylurea therapy at disease onset can cause permanent remission of KATP-induced diabetes, Diabetes, vol.60, issue.10, pp.2515-2537, 2011.

D. Guerrot, M. Kerroch, S. Placier, S. Vandermeersch, C. Trivin et al., Discoidin domain receptor 1 is a major mediator of inflammation and fibrosis in obstructive nephropathy, Am J Pathol, vol.179, issue.1, pp.83-91, 2011.

G. Chen, P. Wang, G. Zhao, G. Xu, A. Gruzdev et al., Cytochrome P450 epoxygenase CYP2J2 attenuates nephropathy in streptozotocin-induced diabetic mice, Prostaglandins Other Lipid Mediat, vol.96, issue.1-4, pp.63-71, 2011.

G. Chen, R. Xu, Y. Wang, P. Wang, G. Zhao et al., Genetic disruption of soluble epoxide hydrolase is protective against streptozotocin-induced diabetic nephropathy, Am J Physiol Endocrinol Metab, vol.303, issue.5, pp.563-75, 2012.

A. A. Elmarakby and J. C. Sullivan, Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy, Cardiovasc Ther, vol.30, issue.1, pp.49-59, 2012.

J. Wada and H. Makino, Inflammation and the pathogenesis of diabetic nephropathy, Clin Sci (Lond), vol.124, issue.3, pp.139-52, 2013.

K. Reidy, H. M. Kang, T. Hostetter, and K. Susztak, Molecular mechanisms of diabetic kidney disease, J Clin Invest, vol.124, issue.6, pp.2333-2373, 2014.

G. Luo, D. C. Zeldin, J. A. Blaisdell, E. Hodgson, and J. A. Goldstein, Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid, Arch Biochem Biophys, vol.357, issue.1, pp.45-57, 1998.

V. Y. Ng, Y. Huang, L. M. Reddy, J. R. Falck, E. T. Lin et al., Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha, Drug Metab Dispos, vol.35, issue.7, pp.1126-1160, 2007.

K. Athirakul, J. A. Bradbury, J. P. Graves, L. M. Degraff, J. Ma et al., Increased blood pressure in mice lacking cytochrome P450 2J5, FASEB J, vol.22, issue.12, pp.4096-108, 2008.

T. C. Delozier, C. C. Tsao, S. J. Coulter, J. Foley, J. A. Bradbury et al., CYP2C44, a new murine CYP2C that metabolizes arachidonic acid to unique stereospecific products, J Pharmacol Exp Ther, vol.310, issue.3, pp.845-54, 2004.

C. Roche, M. Besnier, R. Cassel, N. Harouki, D. Coquerel et al., Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice, Am J Physiol Heart Circ Physiol, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01850659

H. F. Cheng, C. J. Wang, G. W. Moeckel, M. Z. Zhang, J. A. Mckanna et al., Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension, Kidney Int, vol.62, issue.3, pp.929-968, 2002.

K. R. Schmelzer, B. Inceoglu, L. Kubala, I. H. Kim, S. L. Jinks et al., Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors, Proc Natl Acad Sci, vol.103, issue.37, pp.13646-51, 2006.

G. Chen, R. Xu, S. Zhang, Y. Wang, P. Wang et al., CYP2J2 overexpression attenuates non-alcoholic fatty liver disease induced by high fat diet in mice, Am J Physiol Endocrinol Metab, vol.308, issue.2, 2015.

P. A. Craven, M. F. Melhem, S. L. Phillips, and F. R. Derubertis, Overexpression of Cu2+/Zn2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice, Diabetes, vol.50, issue.9, pp.2114-2139, 2001.

. Roche, , p.11

, Author manuscript; available in PMC, Prostaglandins Other Lipid Mediat, 2016.